203 related articles for article (PubMed ID: 30037299)
1. Loss of p53 expression in cancer cells alters cell cycle response after inhibition of exportin-1 but does not prevent cell death.
Marcus JM; Burke RT; Doak AE; Park S; Orth JD
Cell Cycle; 2018; 17(11):1329-1344. PubMed ID: 30037299
[TBL] [Abstract][Full Text] [Related]
2. Molecular mechanism and therapeutic implications of selinexor (KPT-330) in liposarcoma.
Garg M; Kanojia D; Mayakonda A; Said JW; Doan NB; Chien W; Ganesan TS; Chuang LS; Venkatachalam N; Baloglu E; Shacham S; Kauffman M; Koeffler HP
Oncotarget; 2017 Jan; 8(5):7521-7532. PubMed ID: 27893412
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma.
Drakos E; Thomaides A; Medeiros LJ; Li J; Leventaki V; Konopleva M; Andreeff M; Rassidakis GZ
Clin Cancer Res; 2007 Jun; 13(11):3380-7. PubMed ID: 17545546
[TBL] [Abstract][Full Text] [Related]
4. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
[TBL] [Abstract][Full Text] [Related]
5. MDM2 inhibitor Nutlin-3a suppresses proliferation and promotes apoptosis in osteosarcoma cells.
Wang B; Fang L; Zhao H; Xiang T; Wang D
Acta Biochim Biophys Sin (Shanghai); 2012 Aug; 44(8):685-91. PubMed ID: 22843172
[TBL] [Abstract][Full Text] [Related]
6. Activation of p53 by Nutlin-3a, an antagonist of MDM2, induces apoptosis and cellular senescence in adult T-cell leukemia cells.
Hasegawa H; Yamada Y; Iha H; Tsukasaki K; Nagai K; Atogami S; Sugahara K; Tsuruda K; Ishizaki A; Kamihira S
Leukemia; 2009 Nov; 23(11):2090-101. PubMed ID: 19710698
[TBL] [Abstract][Full Text] [Related]
7. Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma.
Nakayama R; Zhang YX; Czaplinski JT; Anatone AJ; Sicinska ET; Fletcher JA; Demetri GD; Wagner AJ
Oncotarget; 2016 Mar; 7(13):16581-92. PubMed ID: 26918731
[TBL] [Abstract][Full Text] [Related]
8. Nutlin sensitizes lung carcinoma cells to interferon-alpha treatment in MDM2-dependent but p53-independent manner.
Shuvalov O; Kizenko A; Shakirova A; Fedorova O; Petukhov A; Aksenov N; Vasileva E; Daks A; Barlev N
Biochem Biophys Res Commun; 2018 Jan; 495(1):1233-1239. PubMed ID: 29175211
[TBL] [Abstract][Full Text] [Related]
9. Longitudinal tracking of single live cancer cells to understand cell cycle effects of the nuclear export inhibitor, selinexor.
Marcus JM; Burke RT; DeSisto JA; Landesman Y; Orth JD
Sci Rep; 2015 Sep; 5():14391. PubMed ID: 26399741
[TBL] [Abstract][Full Text] [Related]
10. Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21).
Drakos E; Singh RR; Rassidakis GZ; Schlette E; Li J; Claret FX; Ford RJ; Vega F; Medeiros LJ
Leukemia; 2011 May; 25(5):856-67. PubMed ID: 21394100
[TBL] [Abstract][Full Text] [Related]
11. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines.
Kitagawa M; Aonuma M; Lee SH; Fukutake S; McCormick F
Oncogene; 2008 Sep; 27(40):5303-14. PubMed ID: 18521084
[TBL] [Abstract][Full Text] [Related]
12. Nutlin-3a: A Potential Therapeutic Opportunity for TP53 Wild-Type Ovarian Carcinomas.
Crane EK; Kwan SY; Izaguirre DI; Tsang YT; Mullany LK; Zu Z; Richards JS; Gershenson DM; Wong KK
PLoS One; 2015; 10(8):e0135101. PubMed ID: 26248031
[TBL] [Abstract][Full Text] [Related]
13. p53 promotes AKT and SP1-dependent metabolism through the pentose phosphate pathway that inhibits apoptosis in response to Nutlin-3a.
Duan L; Perez RE; Chen L; Blatter LA; Maki CG
J Mol Cell Biol; 2018 Aug; 10(4):331-340. PubMed ID: 29190376
[TBL] [Abstract][Full Text] [Related]
14. Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma.
Green AL; Ramkissoon SH; McCauley D; Jones K; Perry JA; Hsu JH; Ramkissoon LA; Maire CL; Hubbell-Engler B; Knoff DS; Shacham S; Ligon KL; Kung AL
Neuro Oncol; 2015 May; 17(5):697-707. PubMed ID: 25366336
[TBL] [Abstract][Full Text] [Related]
15. Restoration of p53 pathway by nutlin-3 induces cell cycle arrest and apoptosis in human rhabdomyosarcoma cells.
Miyachi M; Kakazu N; Yagyu S; Katsumi Y; Tsubai-Shimizu S; Kikuchi K; Tsuchiya K; Iehara T; Hosoi H
Clin Cancer Res; 2009 Jun; 15(12):4077-84. PubMed ID: 19509161
[TBL] [Abstract][Full Text] [Related]
16. The pseudo-caspase FLIP(L) regulates cell fate following p53 activation.
Lees A; McIntyre AJ; Crawford NT; Falcone F; McCann C; Holohan C; Quinn GP; Roberts JZ; Sessler T; Gallagher PF; Gregg GMA; McAllister K; McLaughlin KM; Allen WL; Egan LJ; Ryan AE; Labonte-Wilson MJ; Dunne PD; Wappett M; Coyle VM; Johnston PG; Kerr EM; Longley DB; McDade SS
Proc Natl Acad Sci U S A; 2020 Jul; 117(30):17808-17819. PubMed ID: 32661168
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of exportin-1 function results in rapid cell cycle-associated DNA damage in cancer cells.
Burke RT; Marcus JM; Orth JD
Oncotarget; 2017 Jun; 8(24):39460-39475. PubMed ID: 28467801
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the antitumor effects of an MDM2 inhibitor, nutlin-3, in feline lymphoma cell lines with or without p53 mutation.
Mochizuki H; Goto-Koshino Y; Sato M; Fujino Y; Ohno K; Tsujimoto H
Vet Immunol Immunopathol; 2012 Jun; 147(3-4):187-94. PubMed ID: 22578852
[TBL] [Abstract][Full Text] [Related]
19. MDM2 inhibitor nutlin-3a induces apoptosis and senescence in cutaneous T-cell lymphoma: role of p53.
Manfé V; Biskup E; Johansen P; Kamstrup MR; Krejsgaard TF; Morling N; Wulf HC; Gniadecki R
J Invest Dermatol; 2012 May; 132(5):1487-96. PubMed ID: 22377766
[TBL] [Abstract][Full Text] [Related]
20. Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death.
Kashyap T; Argueta C; Aboukameel A; Unger TJ; Klebanov B; Mohammad RM; Muqbil I; Azmi AS; Drolen C; Senapedis W; Lee M; Kauffman M; Shacham S; Landesman Y
Oncotarget; 2016 Nov; 7(48):78883-78895. PubMed ID: 27713151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
